Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis

Patent Citations (94)

Non-Patent Literature (157)

• Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J Mol Biol. 293(4):865-81 (1999).Applicant
• Fuh et al., “Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab,” J Biol Chem. 281(10):6625-31 (2006).Applicant
• Lamdan et al., “Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor,” Mol Biosyst. 9(8):2097-106 (2013).Applicant
• Lee et al., “High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold,” J Mol Biol. 340(5):1073-93 (2004).Applicant
• Liang et al., “Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF,” J Biol Chem. 281(2):951-61 (2006).Applicant
• Invitation to Pay Additional Fees for International Patent Application No. PCT/US2016/053454, dated Jan. 27, 2017 (10 pages).Applicant
• Boder et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,” Proc Natl Acad Sci U S A. 97(20):10701-5 (2000).Applicant
• Wu, “Simultaneous humanization and affinity optimization of monoclonal antibodies,” Methods Mol Biol. 207:197-212 (2003).Applicant
• International Search Report and Written Opinion for International Patent Application No. PCT/US2016/053454, dated Apr. 28, 2017 (31 pages).Applicant
• “Dissociation constant—Wikipedia, the free encyclopedia,” retrieved on Jul. 13, 2016, from <https://en.wikipedia.org/wiki/Dissociation_constant> (6 pages).Applicant
• American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, “Guidelines for the management of rheumatoid arthritis: 2002 update,” Arthritis & Rheum. 46(2):328-346 (2002).Applicant
• Adamis et al., “Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate,” Arch Opthalmol. 114(1):66-71 (1996).Applicant
• Agenda for Cambridge Healthtech Institute's Sixth Annual Phage Display Technologies Engineering Protein Therapeutics, Royal Sonesta Hotel, Cambridge, Massachusetts, Apr. 26-27, 2004 (3 pages).Applicant
• Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” N Engl J Med. 331(22):1480-7 (1994).Applicant
• Altiok et al., “Multivalent hyaluronic acid bioconjugates improve sFlt-1 activity in vitro,” Biomaterials. 93:95-105 (2016).Applicant
• Altiok et al., “sFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In Vivo,” PLoS One. 11(6):e0155990 (2016) (14 pages).Applicant
• Baca et al., “Antibody humanization using monovalent phage display,” J Biol Chem. 272(16):10678-84 (1997).Applicant
• Baeva et al., “Bacterial endotoxin detection in hyaluronic acid-based medical devices,” J Biomed Mater Res B Appl Biomater. 105(5):1210-1215 (2017).Applicant
• Barbas et al., “In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity,” Proc Natl Acad Sci U S A. 91(9):3809-13 (1994).Applicant
• Barbas et al., “Selection and evolution of high-affinity human anti-viral antibodies,” Trends Biotechnol. 14(7):230-4 (1996).Applicant
• Barrios et al., “Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor,” J Mol Recognit. 17(4):332-8 (2004).Applicant
• Bass et al., “Hormone phage: An enrichment method for variant proteins with altered binding properties,” Proteins. 8(4):309-14 (1990).Applicant
• Bates et al., “Regulation of microvascular permeability by vascular endothelial growth factors,” J Anat. 200(6):581-97 (2002).Applicant
• Beiboer et al., “Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent,” J Mol Biol. 296(3):833-49 (2000).Applicant
• Bendig, “Humanization of rodent monoclonal antibodies by CDR grafting,” Methods: A Companion to Methods in Enzymology. 8:83-93 (1995).Applicant
• Berkman et al., “Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms,” J Clin Invest. 91(1):153-9 (1993).Applicant
• Bergström et al., “Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy,” Cancer Res. 56(17):4032-9 (1996).Applicant
• Brekken et al., “Vascular endothelial growth factor and vascular targeting of solid tumors,” Anticancer Res. 21(6B):4221-9 (2001).Applicant
• Brekken et al., “Vascular endothelial growth factor as a marker of tumor endothelium,” Cancer Res. 58(9):1952-9 (1998).Applicant
• Brerski et al., “Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity?” MAbs. 2(3):212-20 (2010).Applicant
• Brerski et al., “Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs,” J Immunol. 181(5):3183-92 (2008).Applicant
• Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract,” Cancer Res. 53(19):4727-35 (1993).Applicant
• Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer,” Hum Pathol. 26(1):86-91 (1995).Applicant
• Carmeliet et al., “Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele,” Nature. 380(6573):435-9 (1996).Applicant
• Carmeliet et al., “Angiogenesis in cancer and other diseases,” Nature. 407(6801):249-57 (2000).Applicant
• Carter et al., “High level Escherichia coli expression and production of a bivalent humanized antibody fragment,” Biotechnology (N Y). 10(2):163-7 (1992).Applicant
• Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc Natl Acad Sci U S A. 89(10):4285-9 (1992).Applicant
• Chang et al., “Loop-sequence features and stability determinants in antibody variable domains by high-throughput experiments,” Structure. 22(1):9-21 (2014).Applicant
• Chothia et al., “Canonical structures for the hypervariable regions of immunoglobulins,” J Mol Biol. 196(4):901-17 (1987).Applicant
• Christinger et al., “Crystallization of the receptor binding domain of vascular endothelial growth factor,” Proteins. 26(3):353-7 (1996).Applicant
• Clackson et al., “Making antibody fragments using phage display libraries,” Nature. 352(6336):624-8 (1991).Applicant
• Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Res Immunol. 145(1):33-6 (1994).Applicant
• Cooke et al., “A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor:receptor complex,” Cancer Res. 61(9):3653-9 (2001).Applicant
• Cunningham et al., “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis,” Science. 244(4908):1081-5 (1989).Applicant
• de Wildt et al., “Antibody arrays for high-throughput screening of antibody-antigen interactions,” Nat Biotechnol. 18(9):989-94 (2000).Applicant
• Declaration of Germaine Fuh dated Oct. 3, 2012 (4 pages).Applicant
• Deng et al., “Selection of antibody single-chain variable fragments with improved carbohydrate binding by phage display,” J Biol Chem. 269(13):9533-8 (1994).Applicant
• Deshayes et al., “Rapid identification of small binding motifs with high-throughput phage display: Discovery of peptidic antagonists of IGF-1 function,” Chem Biol. 9(4):495-505 (2002).Applicant
• Drescher, “Characterization of biological interactions with Biacore,” GE Healthcare, dated Jun. 27, 2011 (25 pages).Applicant
• Dvorak et al., “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis,” Am J Pathol. 146(5):1029-39 (1995).Applicant
• E-mail from Cambridge Healthtech Institute, “Germaine Fuh at Phage Display Technologies—Apr. 26-27, 2004,” dated Jul. 15, 2016 (2 pages).Applicant
• Ferrara et al., “Clinical applications of angiogenic growth factors and their inhibitors,” Nat Med. 5(12):1359-1364 (1999).Applicant
• Ferrara et al., “Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene,” Nature. 380(6573):439-42 (1996).Applicant
• Ferrara et al., “Molecular and biological properties of the vascular endothelial growth factor family of proteins,” Endo Rev. 13(1):18-32 (1992).Applicant
• Ferrara et al., “Ten years of anti-vascular endothelial growth factor therapy,” Nat Rev Drug Discov. 15(6):385-403 (2016).Applicant
• Ferrara et al., “The biology of vascular endothelial growth factor,” Endocr Rev. 18(1):4-25 (1997).Applicant
• Ferrara et al., “Vascular endothelial growth factor is essential for corpus luteum angiogenesis,” Nat Med. 4(3):336-340 (1998).Applicant
• Ferrara, “Molecular and biological properties of vascular endothelial growth factor,” J Mol Med (Berl). 77(7):527-43 (1999).Applicant
• Folkman et al., “Angiogenic factors,” Science. 235(4787):442-7 (1987).Applicant
• Fuh et al., “Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor,” J Biol Chem. 273(18):11197-204 (1998).Applicant
• Fuh, “Antibodies with ligand-like epitope from phage libraries,” Department of Protein Engineering, Genentech, Inc., Apr. 2004 (21 pages).Applicant
• Garrard et al., “Selection of an anti-IGF-1 Fab from a Fab phage library created by mutagenesis of multiple CDR loops,” Gene. 128(1):103-9 (1993).Applicant
• Gerber et al., “Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies,” Proc Natl Acad Sci U S A. 104(9):3478-83 (2007).Applicant
• Gerber et al., “VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation,” Nat Med. 5(6):623-8 (1999).Applicant
• Gerber et al., Report: Binding of 10 Fab fragments to human VEGF mutants. Life Sciences and Facility Management, Zurich University of Applied Sciences. Aug. 2, 2016 (14 pages).Applicant
• Gerber et al., Report: Expression, purification and VEGF binding of 10 Fab fragments. Life Sciences and Facility Management, Zurich University of Applied Sciences. Jun. 27, 2016 (18 pages).Applicant
• Gerber et al., Report: Inhibition of binding of VEGF to VEGF receptors by 10 Fab fragments. Life Sciences and Facility Management, Zurich University of Applied Sciences. Sep. 8, 2016 (7 pages).Applicant
• Gershoni et al., “Epitope mapping: the first step in developing epitope-based vaccines,” BioDrugs. 21(3):145-56 (2007).Applicant
• Gong et al., “Releasable Conjugation of Polymers to Proteins,” Bioconjug Chem. 26(7):1172-81 (2015) (10 pages).Applicant
• Griffiths et al., “Isolation of high affinity human antibodies directly from large synthetic repertoires,” EMBO J. 13(14):3245-60 (1994).Applicant
• Guerrin et al., “Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro,” J Cell Physiol. 164(2):385-94 (1995).Applicant
• Hawkins et al., “Selection of phage antibodies by binding affinity. Mimicking affinity maturation,” J Mol Biol. 226(3):889-96 (1992).Applicant
• Hecht et al., “A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer,” J Clin Oncol. 27(5):672-80 (2009).Applicant
• Holash et al., “VEGF-trap: a VEGF blocker with potent antitumor effects,” Proc Natl Acad Sci U S A. 99(17):11393-8 (2002).Applicant
• Holliger et al., “Diabodies: Small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci U S A. 90(14):6444-8 (1993).Applicant
• Hoogenboom et al., “Antibody phage display technology and its applications,” Immunotechnology. 4(1):1-20 (1998).Applicant
• Houck et al., “The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA,” Mol Endocrinol. 5(12):1806-14 (1991).Applicant
• Hsu et al., “Antibody variable domain interface and framework sequence requirements for stability and function by high-throughput experiments,” Structure. 22(1):22-34 (2014) (13 pages).Applicant
• Jackson et al., “In vitro antibody maturation: Improvement of a high affinity, neutralizing antibody against IL-1 Beta,” J Immunol. 154(7):3310-9 (1995).Applicant
• Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature. 321(6069):522-5 (1986).Applicant
• Kim et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature. 362(6423):841-4 (1993).Applicant
• Kim et al., “The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies,” Growth Factors. 7(1):53-64 (1992).Applicant
• Kitzman et al., “Massively parallel single-amino-acid mutagenesis,” Nat Methods. 12(3):203-6 (2015) (8 pages).Applicant
• Klagsbrun et al., “Regulators of angiogenesis,” Annu Rev Physiol. 53:217-39 (1991).Applicant
• Klohs et al., “Antiangiogenic agents,” Curr Opin Biotechnol. 10(6):544-9 (1999).Applicant
• Knappik et al., “Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides,” J Mol Biol. 296(1):57-86 (2000).Applicant
• Kobrin et al., “A V region mutation in a phosphocholine-binding monoclonal antibody results in loss of antigen binding,” J Immunol. 146(6):2017-20 (1991).Applicant
• Koenig et al., “Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding,” Proc Natl Acad Sci U S A. 114(4):E486-E495 (2017).Applicant
• Lambrechts et al., “Markers of response for the antiangiogenic agent bevacizumab,” J Clin Oncol. 31(9):1219-30 (2013).Applicant
• Leung et al., “Vascular endothelial growth factor is a secreted angiogenic mitogen,” Science. 246(4935):1306-9 (1989).Applicant
• Li et al., “Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization,” J Biol Chem. 275(38):29823-8 (2000).Applicant
• Lowman et al., “Monovalent phage display: A method for selecting variant proteins from random libraries,” Methods: A Companion to Methods in Enzymology. 3(3):205-216 (1991).Applicant
• Lowman et al., “Selecting high-affinity binding proteins by monovalent phage display,” Biochemistry. 30(45):10832-8 (1991).Applicant
• Lowman, “Optimization of therapeutic antibodies using monovalent phage display,” Presentation for Bio 2002 Conference, Jun. 12, 2002 (22 pages).Applicant
• MacCallum et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J Mol Biol. 262(5):732-45 (1996).Applicant
• Marks et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,” J Mol Biol. 222(3):581-97 (1991).Applicant
• Mattern et al., “Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma,” Br J Cancer. 73(7):931-4 (1996).Applicant
• Melnyk et al., “Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth,” Cancer Res. 56(4):921-4 (1996).Applicant
• Mian et al., “Structure, function, and properties of antibody binding sites,” J Mol Biol. 217(1):133- 51 (1991).Applicant
• Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” Proc Natl Acad Sci U S A. 81(21):6851-5 (1984).Applicant
• Morrison et al., “Combinatorial alanine-scanning,” Curr Opin Chem Biol. 5(3):302-7 (2001).Applicant
• Muller et al., “Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site,” Proc Natl Acad Sci U S A. 94(14):7192-7 (1997).Applicant
• Muller et al., “VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface,” Structure. 6(9):1153-67 (1998).Applicant
• Oberg-Welsh et al., “Effects of vascular endothelial growth factor on pancreatic duct cell replication and the insulin production of fetal islet-like cell clusters in vitro,” Mol Cell Encodrinol. 126(2):125-32 (1997).Applicant
• Pan et al., “Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor,” J Mol Biol. 316(3):769-87 (2002).Applicant
• Papadopoulos et al., “Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab,” Angiogenesis. 15(2):171-85 (2012).Applicant
• Paul, Chapter 9: Structure and Function of Immunoglobulins. Fundamental Immunology, Third Edition. Raven Press Ltd., 292-295 (1993).Applicant
• Pelegri-O'Day et al., “Therapeutic protein-polymer conjugates: advancing beyond PEGylation,” J Am Chem Soc. 136(41):14323-32 (2014).Applicant
• Pini et al., “Design and use of a phage display library: Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel,” J Biol Chem. 273(34):21769-76 (1998).Applicant
• Plückthun, Antibodies from Escherichia coli. The Pharmacology of Monoclonal Antibodies. Rosenberg & Moore, 269-315 (1994).Applicant
• Popkov et al., “Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library,” J Immunol Methods. 288(1-2):14964 (2004).Applicant
• Popkov et al., “Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: The impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display,” J Moi Biol. 325(2):325-35 (2003).Applicant
• Presta, “Antibody engineering,” Curr Op Struct Biol. 2(4):593-6 (1992).Applicant
• Presta et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Res. 57(20):4593-9 (1997).Applicant
• Rai et al., Chronic Lymphocytic Leukemia. Hematology: Basic Principles and Practice. Hoffman, 1350-1363 (2000).Applicant
• Riechmann et al., “Reshaping human antibodies for therapy,” Nature. 332(6162):323-7 (1988).Applicant
• Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci U S A. 79(6):1979-83 (1982).Applicant
• Sato, “Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy,” Int J Clin Oncol. 8(4):200-6 (2003).Applicant
• Schlaeppi et al., “Characterization of a new potent, in vivo neutralizing monoclonal antibody to human vascular endothelial growth factor,” J Cancer Res Clin Oncol. 125(6):336-42 (1999).Applicant
• Shima et al., “The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences,” J Biol Chem. 271(7):3877-83 (1996).Applicant
• Sidhu et al., “Phage display for selection of novel binding peptides,” Methods Enzymol. 328:333-63 (2000).Applicant
• Sidhu et al., “Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions,” J Mol Biol. 338(2):299-310 (2004).Applicant
• Siemeister et al., “The alpha-helical domain near the amino terminus is essential for dimerization of vascular endothelial growth factor,” J Biol Chem. 273(18):11115-20 (1998).Applicant
• Siemeister et al., “The pivotal role of VEGF in tumor angiogenesis: Molecular facts and therapeutic opportunities,” Cancer Metastasis Rev. 17(2):241-8 (1998).Applicant
• Sone et al., “Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice,” Biochem Biophys Res Commun. 281(2):562-8 (2001).Applicant
• Stella et al., Prodrugs: A Chemical Approach to Targeted Drug Delivery. Directed Drug Delivery: A Multidisciplinary Problem. Borchardt, Repta, Stella, 247-267 (1985).Applicant
• Streit et al., “Angiogenesis, lymphangiogenesis, and melanoma metastasis,” Oncogene. 22(20):3172-9 (2003).Applicant
• Sugihara et al., “A novel alternatively spliced form of murine vascular endothelial growth factor, VEGF 115,” J Biol Chem. 273(5):3033-8 (1998).Applicant
• Tol et al., “Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer,” N Engl J Med. 360(6):563-72 (2009).Applicant
• Tonini et al., “Molecular basis of angiogenesis and cancer,” Oncogene. 22(42):6549-56 (2003).Applicant
• van Besien et al., Clinical Manifestations, Staging, and Treatment of Non-Hodgkin Lymphoma. Hematology: Basic Principles and Practice. Hoffman, 1293-1339 (2000).Applicant
• Vaughan et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nat Biotechnol. 14(3):309-14 (1996).Applicant
• Verhoeyen et al., “Reshaping human antibodies: Grafting an antilysozyme activity,” Science. 239(4847):1534-6 (1988).Applicant
• Viloria-Petit et al., “Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors,” EMBO J. 22(16):4091-102 (2003).Applicant
• Wang et al., “Inhibition of Expression Mouse Fibrosarcoma Growth by a Monoclonal Antibody to Human Vascular Endothelial Growth Factor,” Zhongguo Koucliang Hemian Waike Zashi. 1(1):35-9 (2003).Applicant
• Warren et al., “Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis,” J Clin Invest. 95(4):1789-97 (1995).Applicant
• Wells et al., “Rapid evolution of peptide and protein binding properties in vitro,” Curr Opin Biotechnol. 3(4):355-62 (1992).Applicant
• Welti et al. “Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer,” J Clin Invest. 123(8):3190-200 (2013).Applicant
• Werther et al., “Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1,” J Immunol. 157(11):4986-4995 (1996).Applicant
• Wiesmann et al., “Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor,” Cell. 91(5):695-704 (1997).Applicant
• Wilman, “Prodrugs in cancer chemotherapy,” Biochem Soc Trans. 14(2):375-82 (1986).Applicant
• Wu et al., “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J Mol Biol. 294(1):151-62 (1999).Applicant
• Yang et al., “Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A,” Mol Pharm. 11(10):3421-30 (2014).Applicant
• Yelton et al., “Affinity maturation of the BR96 anti-carcinoma antibody by codon-based mutagenesis,” J Immunol. 155(4):1994-2004 (1995).Applicant
• Yu et al., “A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models,” PLoS One. 5(2):e9072 (2010) (12 pages).Applicant
• Yu et al., “Interactions between bevacizumab and murine VEGF-A: A reassessment,” Invest Ophthalmol Vis Sci. 49(2):522-7 (2008).Applicant
• Zapata et al., “Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity,” Protein Eng. 8(10):1057-62 (1995).Applicant
• Zemlin et al., “Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures,” J Mol Biol. 334(4):733-49 (2003).Applicant
• Zola, Using monoclonal antibodies: Soluble antigens. Monoclonal antibodies: A manual of techniques. CRC Press, Inc., 147-181 (2000).Applicant
• International Preliminary Report on Patentability for International Patent Application No. PCT/US2004/024662, dated Feb. 6, 2006 (12 pages).Applicant
• International Preliminary Report on Patentability for International Patent Application No. PCT/US2004/029332, dated Jul. 3, 2006 (12 pages).Applicant
• International Search Report for International Patent Application No. PCT/US2004/024662, dated Oct. 14, 2005 (6 pages.Applicant
• International Search Report for International Patent Application No. PCT/US2004/029332, dated Oct. 14, 2005 (6 pages).Applicant
• Protest Against Norwegian Patent Application No. 20061014, dated Jan. 25, 2017 (13 pages).Applicant
• Summons to Attend Oral Proceedings for European Patent Application No. 04779660.2, dated Apr. 26, 2017 (20 pages).Applicant
• Third Party Observations for European Patent Application No. 04779660.2, submitted Sep. 19, 2016 (26 pages).Applicant
• Third Party Observations for European Patent Application No. 10009691.6, dated Jan. 22, 2016 (10 pages).Applicant